|
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex Trial
Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells.OSLO--(BUSINESS WIRE)--Mar 16, 2010 - PCI Biotech reported today that it has completed the treatment of the third dose group in...
|
|
|
Medical News: PCI Biotech Reports Successful Completion Of The Third Dose Group In The Phase I/II Amphinex(R) Trial
PCI Biotech reported that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Medical News: PCI Biotech...
|
|
|
Norwegian PCI Biotech completes 3rd dose group in Amphinex cancer trial
- Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said yesterday it successfully completed the third dose group in its phase I/II trial with its proprietary photosensitiser Amphinex in combination with bleomycin in cancer patients....
|
|
|
PCI Biotech Reports Successful Completion Of The Third Dose Group In The Phase I/II Amphinex(R) Trial
PCI Biotech reported that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical regression...
|
|
|
PCI Biotech Holding (NO) - Successful completion of the third dose group in the Amphinex study. Continued good
- PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical...
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex Trial
Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells.To date eleven patients have been given a single photochemical internalisation (PCI) treatment with Amphinex. Patients with...
|
|
|
Norwegian PCI Biotech completes 3rd dose group in Amphinex cancer trial
17 March 2010 - Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said yesterday it successfully completed the third dose group in its phase I/II trial with its proprietary photosensitiser Amphinex in combination with bleomycin in...
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex Trial
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical...
|
|
|
PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical...
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical...
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex Trial
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.Complete clinical...
|
|
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex Trial
Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells.PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary...
|
|
|
Radiation Avoided in Early Hodgkin's Lymphoma
Modalities - Radiology Harvard researchers said that young patients with early Hodgkin's lymphoma can be spared from radiotherapy by the so-called ABVD chemotherapy regimen.The basic regimen involves six cycles of doxorubicin, bleomycin, vinblastine...
|
|
|
Influence of p53 expression on sensitivity of cancer cells to bleomycin
In this study, we determined whether p53 expression affected the sensitivity of non-small cell lung cancer (NSCLC) and colon cancer cells to bleomycin (BLM).Two human NSCLC cell lines (A549 expressing wild-type p53 and p53-null H1299) and two colon...
Journal of Biochemical and Molecular Toxicology:
Mar 12 2010 10:47AM
Matching: bleomycin
|
Find similar documents
|
|
|
|
Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer
Testicular cancer is curable in the majority of men, and persisting treatment toxicity is a concern.The authors report a cross-sectional study of the long-term effects of chemotherapy (C) on neurologic function and development of Raynaud phenomenon.Seven...
|
|
|
Management of Cancer Patients in ICU
Management of cancer patients in a critical care set-up is a challenging task.These patients are different from our regular ICU patients such that they may have undergone chemotherapy and/ or radiotherapy or a major debilitating surgery. ICU care is given...
|
|
|
Analysis of association between bleomycin hydrolase and apolipoprotein E polymorphism in Alzheimers disease
Smach MA et al.Alzheimers disease (AD) is the leading cause of dementia. Several studies indicate a possible relationship between different genes and Alzheimers disease. The frequency of ApoE epsilon 4 allele was found to differ significantly in AD...
|
|
|
High-Dose Sequential Chemo Does Not Improve Outcomes in Poor-Prognosis Germ Cell Tumours: Presented at ASCO-GU
-- A phase 3 trial presented here at the 2010 Genitourinary Cancers Symposium (ASCO-GU) has found that high-dose sequential chemotherapy does not improve outcomes as a first-line treatment for advanced, poor-prognosis germ cell tumours.The trial was ended...
|
|
|
Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposis Sarcoma in Western Kenya
Reducing the Worldwide Burden of Cancer Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi?s Sarcoma in Western Kenya R.Matthew Strothera, Kelly M. Gregoryb, Sonak D. Pastakiab, Pamela Wered, f, Constance...
|
|
|
The Role of Surfactant Protein A in Bleomycin-induced Acute Lung Injury
Goto H et al.The Role of Surfactant Protein A in Bleomycin-induced Acute Lung Injury.
|
|
|
Influence of Suboptimal Treatment in Patients with Mediastinal Primary Nonseminomatous Germ Cell Tumors
Kan Yonemoria, Tsutomu Kounoa, Masashi Andoa, Akihiro Hirakawab, Harukaze Yamamotoa, Makiko Onoa, Taizo Hirataa, Chikako Shimizua, Kenji Tamuraa, Noriyuki Katsumataa, Yasuhiro Fujiwaraa aBreast and Medical Oncology Division, National Cancer Center Hospital,...
|
|
|
Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation
George P.Canellos,* Jeremy S. Abramson, David C. Fisher, and Ann S. LaCasce From the Medical Oncology/Hematology, Dana-Farber Cancer Institute; Massachusetts General Hospital; Harvard Medical School, Boston, MA. * To whom correspondence should be...
|
|
|
Chemotherapy plus ART best treatment for Kaposi's sarcoma in South African study
Treating severe Kaposi's sarcoma in South Africa is more likely to be successful when chemotherapy is used alongside antiretroviral therapy, researchers from the University of Kwazulu-Natal reported this week at the Seventeenth Conference on Retroviruses and...
|
|
|
Norwegian PCI Biotech Q4 '09 net loss narrows
- Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said today its net loss shrank to NOK3.6m in the fourth quarter of 2009 from NOK8.4m in the same period in 2008, according to preliminarily figures.In the fourth quarter of 2009, the...
|
|
|
Norwegian PCI Biotech Q4 '09 net loss narrows
- Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said today its net loss shrank to NOK3.6m in the fourth quarter of 2009 from NOK8.4m in the same period in 2008, according to preliminarily figures.In the fourth quarter of 2009, the...
|
